Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and… Read more
Kyntra Bio, Inc. (KYNB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.106x
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has a cash flow conversion efficiency ratio of -0.106x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.85 Million) by net assets ($17.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kyntra Bio, Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Kyntra Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kyntra Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyntra Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Argentum Silver Corp
PINK:AGSVF
|
0.135x |
|
INTL ZEOLITE
F:ZEON
|
N/A |
|
CYBERAGENT (CL2.SG)
STU:CL2
|
N/A |
|
Canadian Banc Corp
PINK:CNDCF
|
-0.078x |
|
RENT3F
SA:RENT3F
|
N/A |
|
BIOCRYST PHARM
MU:BO1
|
-0.018x |
|
A S CREATION TAP N - Dusseldorf Stock Exchang
DU:ACWN
|
0.013x |
|
Syncona Limited
LSE:SYNC
|
0.006x |
Annual Cash Flow Conversion Efficiency for Kyntra Bio, Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Kyntra Bio, Inc. from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |